GET DAILY SIGNALSKrystal Biotech (KRYS) Delivers +30% VYJUVEK Revenue Growth in Q3 2026
Key Takeaways
- Global VYJUVEK net revenue rose 30% year over year to $127.3 million in the third quarter of 2026.
- Diluted earnings per share (EPS) of $2.05 and revenue of $127.3 million both topped analyst consensus estimates.
- Net income fell to $63.1 million from $79.4 million a year earlier, mainly because of a non-recurring tax-benefit swing.
- Management lowered full-year non-GAAP research and development (R&D) and selling, general, and administrative (SG&A) expense guidance to $155–$165 million.
- The board authorized a $400 million share repurchase program to be deployed over the next two years.
- Shares dropped sharply despite the beat as several clinical readouts were pushed into 2027.
Putting the Results in Context
Krystal Biotech is a commercial-stage gene therapy company whose lead product, KRYS, is the first and only approved treatment for dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disorder. The third-quarter report matters because it tests whether the company can keep converting VYJUVEK's commercial momentum into durable profitability while funding an expanding pipeline. With cumulative VYJUVEK sales now exceeding $1.1 billion since launch, investors are watching both the pace of U.S. and international adoption and the timing of new clinical data that could diversify the business beyond a single product. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter in Numbers
For the third quarter ended September 30, 2026, Krystal Biotech reported global VYJUVEK net revenue of $127.3 million, a 30% increase from $97.8 million in the prior-year period. U.S. net revenue reached $95.3 million, while international revenue climbed to approximately $32 million, driven by launches in Europe and Japan. Diluted EPS came in at $2.05, above the consensus estimate of $1.92, and revenue also edged past analyst expectations of roughly $126.5 million.
Net income declined to $63.1 million, or $2.13 per basic share, from $79.4 million, or $2.74 per basic share, a year ago. The decrease largely reflected a tax swing: the prior-year quarter included a $31.4 million income tax benefit, whereas the current quarter recorded $17.1 million of income tax expense. Operating income, by contrast, rose sharply to $71.1 million from $41.4 million a year earlier. Gross margin eased to 94% from 96%, reflecting higher international sales that have not yet benefited from U.S. manufacturing process optimizations.
The company also updated its outlook, lowering full-year non-GAAP R&D and SG&A expense guidance to $155–$165 million from a prior range of $175–$195 million, and announced a $400 million share repurchase authorization. From what I see, the expense reduction and buyback together signal disciplined capital allocation.
How the Market Responded
Despite a top- and bottom-line beat, Krystal Biotech shares fell more than 10% intraday following the report. The decline reflected investor focus on the pipeline rather than the strong quarter: management disclosed that several clinical readouts originally expected around year-end have been pushed into 2027, including KB803 for ocular DEB, KB801 for neurotrophic keratitis, and interim KB407 data in cystic fibrosis. Analysts suggested the move may have been exaggerated, but the delay in near-term catalysts overshadowed otherwise solid commercial execution and the new buyback authorization.
What to Watch Going Forward
Looking ahead, investors will be watching whether VYJUVEK's growth can sustain its momentum as international launches mature. Pricing negotiations have concluded in Germany and Italy, with an Italian launch expected in early 2027, while decisions in Spain are anticipated by year-end. These reimbursement milestones provide clearer visibility into the ex-U.S. opportunity.
On the pipeline, near-term catalysts include a KB111 data update in Hailey-Hailey disease before year-end and the start of regulatory conversations with the U.S. Food and Drug Administration (FDA) following encouraging early KB113 results in Gorlin syndrome. Management also confirmed a 2027 registrational start for KB407 in cystic fibrosis.
Key factors to monitor include the pace of patient enrollment across delayed programs, gross margin trends as international revenue grows, and how the company deploys capital between pipeline investment and the newly authorized share repurchase. The reduced expense guidance partly reflects slower trial spending, so investors will want to distinguish genuine efficiency gains from deferred development activity. I’m watching this closely as the company balances growth with shareholder returns.
Using Tickeron’s AI Screener in My Workflow
One tool I regularly turn to when reviewing earnings and pipeline updates is Tickeron’s AI Screener. It helps me quickly filter stocks by fundamentals, technical patterns, and industry benchmarks, which adds useful context when evaluating names like KRYS alongside peers. The platform’s customizable scans have become a practical part of how I prepare for quarterly reports and assess relative value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KRYS sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for KRYS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 45 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 259 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 83 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 42 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for KRYS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.444) is normal, around the industry mean (3.104). P/E Ratio (35.780) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company which provides therapies for rare and orphan diseases
Industry Biotechnology
Advertisement